Development of 3-hydroxycinnamamide-based HDAC inhibitors with potent in vitro and in vivo anti-tumor activity

European Journal of Medicinal Chemistry

Volumn 89, Issue , 2015, Pages 628-637

  Li, Xiaoyang ^a   Hou, Jinning ^a   Li, Xiaoguang ^a   Jiang, Yuqi ^a   Liu, Xueliang ^a   Mu, Weiwei ^a   Jin, Yiming ^a   Zhang, Yingjie ^a   Xu, Wenfang ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

Anti tumor drugs; Antiproliferative activity; HDACIs; HDACs; In vivo oral activity

Indexed keywords

ANTINEOPLASTIC AGENT; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; INDOLE DERIVATIVE; N-(1-(3-(3-(HYDROXYAMINO)-3-OXOPROP-1-EN-1-YL)PHENOXY)-3-(1H-INDOL-3-YL)PROPAN-2-YL)-4-METHOXYBENZAMIDE;

APOPTOSIS; CELL PROLIFERATION; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; DRUG SCREENING; HUMAN; METABOLISM; STRUCTURE ACTIVITY RELATION; SYNTHESIS; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; INDOLES; MOLECULAR STRUCTURE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84908668147     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2014.10.077     Document Type: Article

References (16)

1. L.S. Kristensen, H.M. Nielsen, L.L. Hansen, Epigenetics and cancer treatment, Eur. J. Pharmacol. 625 (1) (2009) 131-142.
2. J.G. Herman, S.B. Baylin, Gene silencing in cancer in association with promoter hypermethylation, N. Engl. J. Med. 349 (21) (2003) 2042-2054.
3. B. Shi, W. Xu, The development and potential clinical utility of biomarkers for HDAC inhibitors, Drug Discov. Ther. 7 (4) (2013).
4. J.S. Carew, F.J. Giles, S.T. Nawrocki, Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy, Cancer Lett. 269 (1) (2008) 7-17.
5. Y. Zhang, H. Fang, J. Jiao, W. Xu, The structure and function of histone deacetylases: the target for anti-cancer therapy, Curr. Med. Chem. 15 (27) (2008) 2840-2849.
6. M.A. Glozak, N. Sengupta, X. Zhang, E. Seto, Acetylation and deacetylation of non-histone proteins, Gene 363 (2005) 15-23.
7. I. Gregoretti, Y.-M. Lee, H.V. Goodson, Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis, J. Mol. Biol. 338 (1) (2004) 17-31.
8. W. Stünkel, R.M. Campbell, Sirtuin 1 (SIRT1) the misunderstood HDAC, J. Biomol. Screen. 16 (10) (2011) 1153-1169.
9. O. Witt, H.E. Deubzer, T. Milde, I. Oehme, HDAC family: what are the cancer relevant targets? Cancer Lett. 277 (1) (2009) 8-21.
10. D.Z. Qian, Y. Kato, S. Shabbeer, Y. Wei, H.M. Verheul, B. Salumbides, T. Sanni, P. Atadja, R. Pili, Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589, Clin. Cancer Res. 12 (2) (2006) 634-642.
11. X. Li, J. Zhang, Y. Xie, Y. Jiang, Z. Yingjie, W. Xu, Progress of HDAC inhibitor panobinostat in the treatment of cancer, Curr. Drug Targets 15 (6) (2014) 622-634.
12. H.M. Prince, M.J. Bishton, S.J. Harrison, Clinical studies of histone deacetylase inhibitors, Clin. Cancer Res. 15 (12) (2009) 3958-3969.
13. X. Li, E.S. Inks, X. Li, J. Hou, C.J. Chou, J. Zhang, Y. Jiang, Y. Zhang, W. Xu, Discovery of the first N-hydroxycinnamamide-based histone deacetylase 1/3 dual inhibitors with potent oral antitumor activity, J. Med. Chem. (2014).
14. Y. Zhang, P. Yang, C.J. Chou, C. Liu, X. Wang, W. Xu, Development of n-hydroxycinnamamide-based histone deacetylase inhibitors with an indole-containing cap group, ACS Med. Chem. Lett. 4 (2) (2013) 235-238.
15. Y. Zhang, J. Feng, Y. Jia, X. Wang, L. Zhang, C. Liu, H. Fang, W. Xu, Development of tetrahydroisoquinoline-based hydroxamic acid derivatives: potent histone deacetylase inhibitors with marked in vitro and in vivo antitumor activities, J. Med. Chem. 54 (8) (2011) 2823-2838.
16. Y. Zhang, H. Fang, J. Feng, Y. Jia, X. Wang, W. Xu, Discovery of a tetrahydroisoquinoline-based hydroxamic acid derivative (ZYJ-34c) as histone deacetylase inhibitor with potent oral antitumor activities, J. Med. Chem. 54 (15) (2011) 5532-5539.